• 中国核心期刊(遴选)数据库收录期刊
  • 中文科技期刊数据库收录期刊
  • 中国期刊全文数据库收录期刊
  • 中国学术期刊综合评价数据库统计源期刊等

• 药品评价-临床研究 • 上一篇    下一篇

曲妥珠单抗联合新辅助化疗对乳腺癌患者血管新生因子及乳腺组织中凋亡分子的影响

孟苗   

  1. 河南科技大学第二附属医院
  • 收稿日期:2018-03-21 修回日期:2018-04-09 出版日期:2018-04-25 发布日期:2018-04-25

Effect of Trastuzumab Combined with Neoadjuvant Chemotherapy on Vascular Endothelial Growth Factor and Apoptosis Factors of Breast Tissue in Breast Cancer Patients

mengmiao   

  1. Henan University of Technology Second Affiliated Hospital
  • Received:2018-03-21 Revised:2018-04-09 Online:2018-04-25 Published:2018-04-25

摘要: 目的:观察曲妥珠单抗联合新辅助化疗对HER-2阳性乳腺癌患者血管新生因子(VEGF)及乳腺组织中凋亡分子的影响。方法:将我院2015年12月至2016年11月治疗的106例HER-2阳性乳腺癌患者,依据随机数表法将其分为两组,均53例。两组患者均接受注射用卡铂100 mg溶于葡萄糖注射液(5%)稀释至10 mg?mL-1,随后将其溶于500 mL葡萄糖注射液,于每个化疗周期第1d静脉注射200~400 mg?m2,于每个化疗周期第1天将多西他赛注射液75 mg?m2静脉滴注,观察组加用曲妥珠单抗治疗。观察两组临床疗效、治疗前后血管新生因子、乳腺组织中凋亡分子变化情况。结果:两组治疗总有效率相比,对照组低于观察组,差异有统计学意义(P<0.05);治疗前两组血管新生因子A(VEGFA)、血管新生因子B(VEGFB)、捕获受体3(DcR3)、环氧合酶2(COX-2)水平对比,差异无统计学意义(P>0.05);治疗后观察组VEGFA、VEGFB、DcR3、COX-2水平低于对照组,差异有统计学意义(P<0.05)。结论:曲妥珠单抗与新辅助化疗联合应用于乳腺癌治疗中效果确切,可调节患者血管新生因子、乳腺组织中凋亡分子水平,提升疾病控制效果。

Abstract: Objective:To observe the effect of tratuzurone combined with neoadjuvant chemotherapy on angiogenesis factor(VEGF) and apoptosis in breast tissue of HER2 positive breast cancer. Methods:106 cases of HER2-positive breast cancer treated in our hospital from December 2015 to November 2016 were divided into two groups according to random number table method, all 53 cases. Both groups were given injection of carboplatin 100 mg dissolved in glucose injection (5%) diluted to 10 mg?mL-1, and then dissolved in 500mL glucose injection, with intravenous injection of 200~400 mg?m2 on the first day of each chemotherapy cycle, then intravenous drip of docetaxel injection 75 mg?m2 on the first day of each chemotherapy cycle. And on this basis, the observation group was treated with tratuzumab. To observe the clinical efficacy, angiogenesis factor and apoptosis in mammary tissue before and after treatment. Results: Compared with the total treatment efficiency, the control group was lower than the observation group, and the difference was statistically significant(P<0.05). The levels of vascular endothelial growth factor A (VEGFA), vascular endothelial growth factor B (VEGFB), capture receptor 3(DcR3), oxide 2(COX-2) in the two groups before treatment were not significantly different(P>0.05). After treatment, the levels of VEGFA, VEGFB, DcR3, COX-2 were lower than those of control group, and the difference was significant(P<0.05). Conclusion: The combination of tratuzurone and neoadjuvant chemotherapy is effective in breast cancer treatment. It can regulate the level of angiogenesis factor and apoptosis in breast tissue and improve the disease control.